Trial site
Clinirem Sp. z o.o.
- 14running trials
- 8closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- CIDP (chronic inflammatory demyelinating polyneuropathy)8 trials
- Myasthenia gravis7 trials
- Alzheimer disease3 trials
- Multiple sclerosis2 trials
- Migraine1 trial
- Trigeminal neuralgia1 trial
- Phase
- Phase 312 trials
- Phase 27 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Status
- Recruiting10 trials
- Completed8 trials
- Active, not recruiting4 trials
- Lead sponsor
- argenx3 trials
- Immunovant Sciences GmbH2 trials
- Janssen Research & Development, LLC2 trials
- Zenas BioPharma (USA), LLC2 trials
- Aurinia Pharmaceuticals Inc.1 trial
- and 12 more
Running trials
Recruiting
Recruiting
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Recruiting
Recruiting
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Active, not recruiting
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Recruiting
Active, not recruiting
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- CIDP (chronic inflammatory demyelinating polyneuropathy)5 recruiting
- Myasthenia gravis3 recruiting
- Multiple sclerosis2 recruiting
Closed trials
Completed
Safety, Tolerability, and Efficacy of NVG-2089 in Participants with CIDP
Completed
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP
Completed
Completed
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Completed
Completed
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Completed
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Site data: EU CTIS (euclinicaltrials.eu)Updated 17 Nov 2026